A U.S. defense agency that specializes in turning science fantasies into realities jump-started technologies and nurtured companies that are now at the forefront of the response to the COVID-19 pandemic.
The Defense Research Advanced Projects Agency (DARPA) has taken risks where others wouldn’t. Its pursuit of high-risk, high-reward technologies, combined with its mission-driven approach to managing projects is promising to pay off in the fight against COVID-19.
DARPA was behind the creation of DNA and RNA vaccines, funding early R&D by Moderna Inc. (NASDAQ: MRNA) and Inovio Pharmaceuticals Inc. (NASDAQ: INO) at a time when the technologies were considered speculative by many scientists and investors.
Comments are closed.